News & Articles
Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive Officer
Rappta Therapeutics announces today the appointment of Sunjeet Sawhney as Chief Executive Officer (CEO) with immediate effect. Rappta’s Co-founder and Founding CEO Mikko Mannerkoski will move to be Chief Financial Officer (CFO) as planned.
Read more
Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs
Unique phosphatase technology platform offers a new paradigm in oncology. EUR 9M financing, co-led by NVF and Novo Seeds with participation from Advent Life Sciences and a family office, to advance lead compounds to clinical candidate stage.
Read more
The Narla Lab
Work in the Narla lab is directed towards the following three interconnected areas: 1) the functional characterization of the regulation of PP2A, 2) identifying the biological and structural basis of cancer-derived mutations in PP2A and, 3) the development and characterization of small molecule activators of PP2A as both chemical tools to probe PP2A regulation and for the treatment of PP2A dependent diseases. The Narla lab is located at the Rogel Cancer Center at the University of Michigan within the Division of Genetic Medicine.
www.thenarlalab.com